Peru

TB drug resistance a fast-growing problem, researchers warn

Researchers on Thursday sounded the alarm over drug-resistant tuberculosis, calling it a curse that was swiftly becoming more difficult and costly to treat.

In eight countries they studied, 43.7% of TB patients did not respond to at least one second-line TB drug, a strategy used when the most powerful first-line drugs fail.

The probe, covering Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea and Thailand, is reported in The Lancet medical journal.

Global war on tobacco far from over

While anti-tobacco legislation and campaigns have increased globally, there is still much that needs to be done to stop the six million people from dying due to smoking cigarettes or second-hand smoke every year.

The 2011 World Health Organization (WHO) Report on the Global Tobacco epidemic found that countries are making significant, measurable progress in implementing large, graphic health warnings on tobacco packages and other proven measures to reduce tobacco use, the world's leading cause of preventable death.

Vaccine crisis on confusion over Zambia

CAPE TOWN — Travel clinics have inadvertently sparked a nationwide shortage of yellow fever vaccines by advising travellers to Zambia to get the shots, even though the country is not on the Department of Health’s list of destinations from which travellers must provide yellow fever certificates before entry into SA.

Children Suffer When Mother Lacks Input, UNICEF Says

UNITED NATIONS (Reuters) - Children are likely to be undernourished in households where women are denied a voice in family decisions like doctor visits, food expenditures and trips to see friends and relatives, says a report by the U.N. Children's Fund, UNICEF, released on Monday.

Major WHO study concludes calcium supplements can reduce complications during pregnancy

Preeclampsia, the development of high blood pressure and protein in the urine during pregnancy and its more severe complications such as eclampsia, can threaten the lives of both mother and child. While there is no therapy to prevent preeclampsia, a link to calcium deficiency has been suggested. In a study published in the March issue of the American Journal of Obstetrics and Gynecology, researchers across the globe, under the auspices of the World Health Organization (WHO), investigated whether a calcium supplement could reduce the complications and mortality from this condition.

Women do not speak of domestic violence - WHO

Geneva/London - One in six women worldwide suffers domestic violence - some battered during pregnancy - yet many remain silent about the assaults, according to the World Health Organisation.

Latin America to set lower prices for HIV treatments

Ten Latin American countries have signed a letter of intent with a number of pharmaceutical companies which opens the way to lower prices for antiretroviral drugs, HIV diagnostic and monitoring tests. While full details have not yet been released, the effect should be substantial: the cost of first-line triple therapy is reduced by between 30 and 92% from the best prices previously available and second-line treatments are also included. The overall impact could be to allow 150,000 more people with HIV to receive treatment in the region without increasing current levels of spending on ARV drugs, according to REDLA+, the Latin American network for positive people and others close to the negotiations. The process had the goal of securing lower prices for the customers in return for access for the suppliers to a larger and more predictable market. The health ministers heard from individual companies privately on the prices they could offer for particular drugs, and then set a reference price as a maximum figure for future purchases of each product. Companies are free to offer lower prices, although there is no expectation that there will be further discounts for bulk orders, etc. The agreement includes conditions on quality control and bio-equivalence studies for generic companies supplying ARVs in the Latin American market, which implies coordination among drug regulators in the region to simplify their procedures and speed product registration without risking patients’ welfare. This agreement was jointly negotiated between the governments of Argentina, Bolivia, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela and a number of pharmaceutical companies. Of the major international pharmaceutical companies, only Abbott (supplier of diagnostics as well as ARVs) has signed up, alongside the generic companies Cipla (India), Combino Pharm (Spain), Filaxis (Argentina), Ranbaxy (India), Refasa (Peru), Richmond (Argentina) and Rontag (Argentina). Of these companies, four - Abbott, Cipla, Combino Pharm and Ranbaxy - now have ARVs pre-qualified for international purchase under the UNAIDS/WHO pilot scheme to assess compliance with good manufacturing practice. Full implementation of this agreement appears to depend on WHO examination of the manufacturing processes and product quality offered by all of the companies involved. BMS, GSK, Merck and Roche declined to participate in the bidding process as they were unwilling to offer a single regional price. Effectively, the agreement now means they must match the prices of the generic companies where there is direct competition, or their products will not be purchased. Gilead Sciences (makers of tenofovir) have also signalled their readiness to offer reduced prices in Latin America although no announcement on this has yet been made. Similar negotiations have recently taken place between groups of pharmaceutical companies and groups of companies in the Caribbean and Central America, but until now the big international pharmaceutical companies have succeeded in excluding generic suppliers from the process. Brazil famously secured large discounts on ARV prices through actual or threatened generic competition, as well as through bulk purchasing. Clearly, Brazil has now become the model for other states to follow. The key question will now be whether other countries will match Brazil's commitment to providing healthcare and treatment, as well as its readiness to stand up to political pressure from the USA and multinational companies: Source: (aidsmap10 June, 2003). http://www.aidsmap.com/news/newsdisplay2.asp?newsId=2109